1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Merck 1Q: Januvia meets CVOT goals; Keytruda ready to go in NSCLC

 
• By Lucie Ellis-Taitt

Merck & Co saw worldwide sales fall by 8% in the first quarter of 2015 but major products met expectations – including diabetes therapy Januvia (sitagliptin), which received further positive news on 27 April when Merck reported the drug didn't increase the risk of heart problems in patients.

Merck & Co saw worldwide sales fall by 8% in the first quarter of 2015 but major products met expectations – including diabetes therapy Januvia (sitagliptin), which received further positive news on 27 April when Merck reported the drug didn't increase the risk of heart problems in patients.

Full results of the cardiovascular outcomes (CVOT) trial for the di-peptidyl peptidase-IV (DPP-4) Januvia will be reported at the American Diabetes Association's annual meeting on 8 June, but Merck said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.